Total
0
Shares
ResApp Health (ASX:RAP) - CEO & Managing Director, Tony Keating
CEO & Managing Director, Tony Keating
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • ResApp Health (RAP) has launched its at-home sleep apnoea screening app, SleepCheck
  • The app diagnoses the risk of sleep apnoea from the user’s snoring and breathing during sleep
  • Sleep apnoea occurs when air stops flowing from the lungs for ten seconds or more during asleep
  • If untreated, the apnoea can cause daytime tiredness and has been linked to serious health conditions
  • SleepCheck requires no extra accessories to run, and can be used with just a smartphone
  • ResApp is up 2.7 per cent on the market this morning, trading shares for 19 cents each

ResApp Health (RAP) has launched its at-home sleep apnoea screening app, SleepCheck.

SleepCheck can be downloaded on a smartphone and analyses a user’s breathing and snoring sounds during sleep. In turn, it can provide an assessment of the user’s risk of developing sleep apnoea.

Sleep apnoea is a medical condition that is associated with loud snoring. It is where air stops flowing from the lungs for ten seconds or longer while asleep. In severe cases, this can happen more than 30 times per hour.

If the sleep apnoea is untreated, it can cause daytime tiredness, reduced work productivity and an impaired immune system. It has been linked to serious health complications such as heart disease, hypertension, stroke and type 2 diabetes.

“Studies have shown that 80 per cent of people with sleep apnoea are undiagnosed,” ResApp said.

It affects more than three in every ten men and nearly two in every ten women.

About the app

SleepCheck requires no extra accessories to run, and can be used with just a smartphone. After downloading the app, users place their smartphone on a bedside table and click the start button.

The app then uses a built-in microphone to test the user’s snoring and breathing.

We are excited to announce that SleepCheck is now available on the App Store. For the first time, consumers have direct access to a clinical-grade, regulatory-approved screening tool for sleep apnoea,” said CEO and Managing Director Tony Keating.

“Over a third of Australian adults do not get the duration or quality of sleep needed, which has major consequences for their health, safety and quality of life. Many adults snore, and loud snoring is an important indicator of sleep apnoea,
although it often is ignored. SleepCheck offers an easy way to check if there’s more to your snore,” he added.

ResApp is up 2.70 per cent on the market this morning, trading shares for 19 cents each at 10:09 am AEST.

RAP by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.